Sunday 18 October 2026
Export ABVC’s income statement to Excel — free account
ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
0.92
0.01
−1.08%
Follow ABVC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 54.20 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (73.29) | |
P/B ratio |
— | — | — | 4.88 | |
Price to Tangible BV |
— | — | — | 4.90 | |
EV/Sales |
— | — | — | 54.83 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (23.06) | |
EV/FCF |
— | — | — | (22.87) | |
Quick Ratio |
0.02 | 0.07 | 0.35 | 0.14 | |
Current Ratio |
0.07 | 0.12 | 0.41 | 0.51 | |
Net Debt/EBITDA |
0.14 | 0.14 | 0.70 | 0.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.07 | |
Operating CF/Net income |
0.33 | 0.57 | 0.21 | 0.47 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(18.43) | (31.83) | (67.45) | (63.37) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 3.76% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 243.03% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 142.74% | |
Graham Net Nets |
— | — | — | (0.05) | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (7.88%) | |
Free Cash Flow Yield |
— | — | — | (4.42%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.03 | |
Operating CF per Share |
(0.01) | (0.04) | (0.03) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.04) | (0.03) | (0.04) | |
Cash per Share |
0.00 | 0.01 | 0.07 | 0.04 | |
Shareholders Equity per Share |
0.47 | 0.50 | 0.66 | 0.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.47 | 0.50 | 0.66 | 0.62 | |
Free Cash Flow |
(0.24) | (0.89) | (0.59) | (0.96) | |
Working Capital |
(5.28) | (4.74) | (3.66) | (3.23) | |
Net Current Asset Value |
(6.72) | (6.26) | (5.26) | (3.41) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.10 | 0.39 | — | |
Average Inventory |
— | — | — | 0.02 | |
Average Assets |
17.82 | 17.30 | 14.30 | 17.84 | |
Average Common Equity |
10.88 | 10.39 | 7.01 | 11.24 |
Columns are period end dates · fundamentals updated 28 Sep 2026